Some GLP-1R agonists, like Liraglutide (taken once daily) or Dulaglutide (taken once weekly), are already licensed for T2D and obesity management in humans due to their ability to mimic the effects of GLP-116–18. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.